Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

8
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
8
Nephrotic Syndrome III : Nursing Management01:24

Nephrotic Syndrome III : Nursing Management

19
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
19
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

7
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
7
Autoimmune Disorders01:29

Autoimmune Disorders

492
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
492
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

1.6K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.6K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

190
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
190

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bilateral renoureteral plasmacytoma. An unusual presentation in a young patient with multiple myeloma.

Revista espanola de medicina nuclear e imagen molecular·2026
Same author

The nuclear oncologist.

Revista espanola de medicina nuclear e imagen molecular·2026
Same author

Therapeutic impact of 18F-PSMA-1007 PET/MRI in staging intermediate/high-risk prostate cancer patients: Imaging biomarkers and radiomic analysis associated with tumor aggressiveness.

Revista espanola de medicina nuclear e imagen molecular·2026
Same author

Early diagnosis of synchronous bilateral breast cancer using bilateral breast-selective prone-position [18F]FDG PET/MRI.

Revista espanola de medicina nuclear e imagen molecular·2026
Same author

Validation of proposals for definitions of moderate and severe disease activity in SLE: impact on flares, quality of life, damage accrual, hospitalisations and mortality.

Lupus science & medicine·2025
Same author

Feasibility of transperineal prostate biopsy guided by fusion of [18F]F-PSMA-1007 PET/MRI with real-time transrectal ultrasound. Prostate cancer classification using imaging biomarkers and radiomics in PIRADS 3 lesions.

Revista espanola de medicina nuclear e imagen molecular·2025

Related Experiment Video

Updated: Jul 16, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.0K

Immunoglobulins in systemic sclerosis management. A large multicenter experience.

J Tandaipan1, A Guillén-Del-Castillo2, C P Simeón-Aznar2

  • 1Department of Rheumatology and Systemic Autoinmune Diseases, Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain.

Autoimmunity Reviews
|September 14, 2023
PubMed
Summary

Intravenous immunoglobulin (IVIG) therapy shows promise in improving muscle, skin, and gastrointestinal symptoms in systemic sclerosis (SSc) patients. This study indicates IVIG is a safe treatment option for managing SSc manifestations in routine clinical care.

Keywords:
Immunoglobulins intravenousMyositisSystemic sclerosisTreatment

More Related Videos

Author Spotlight: A Focus on Standardized Salivary Gland Ultrasound Protocol in Connective Tissue Disease Research
07:25

Author Spotlight: A Focus on Standardized Salivary Gland Ultrasound Protocol in Connective Tissue Disease Research

Published on: October 13, 2023

2.4K
Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry
12:36

Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry

Published on: June 26, 2018

9.5K

Related Experiment Videos

Last Updated: Jul 16, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.0K
Author Spotlight: A Focus on Standardized Salivary Gland Ultrasound Protocol in Connective Tissue Disease Research
07:25

Author Spotlight: A Focus on Standardized Salivary Gland Ultrasound Protocol in Connective Tissue Disease Research

Published on: October 13, 2023

2.4K
Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry
12:36

Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry

Published on: June 26, 2018

9.5K

Area of Science:

  • Rheumatology
  • Immunology
  • Clinical Medicine

Background:

  • Systemic sclerosis (SSc) is a complex autoimmune disease characterized by ত্বক hardening and organ damage.
  • Current treatment options for SSc have limitations, necessitating exploration of alternative therapies.
  • Intravenous immunoglobulin (IVIG) is an immunomodulatory therapy with potential applications in autoimmune diseases.

Purpose of the Study:

  • To evaluate the effectiveness of IVIG in treating various organ manifestations of SSc.
  • To assess the safety and tolerability of IVIG in SSc patients.
  • To identify patient subgroups that may benefit most from IVIG therapy.

Main Methods:

  • Retrospective multicenter observational study of SSc patients treated with IVIG.
  • Data collection included epidemiological parameters, clinical outcomes, and adverse events.
  • Key parameters assessed: modified Rodnan Skin Score (mRSS), muscle strength (MRC), creatine kinase (CK) levels, and gastrointestinal (UCLA GIT 2.0) and pulmonary function tests.

Main Results:

  • Significant improvements observed in muscular involvement (MRC, CK levels) and skin scores (mRSS) post-IVIG.
  • Positive trends noted in gastrointestinal symptom scores (UCLA GIT 2.0).
  • IVIG demonstrated a favorable safety profile with a low incidence of serious adverse events.

Conclusions:

  • IVIG may be an effective treatment for myositis, gastrointestinal, and cutaneous manifestations in SSc patients.
  • The safety profile of IVIG supports its use in routine SSc care.
  • Further research may elucidate optimal IVIG protocols for specific SSc patient subgroups.